Cornerstone Planning Group
ACXP icon

Cornerstone Planning Group’s Acurx Pharmaceuticals ACXP Stock Holding History

Cornerstone Planning Group’s Portfolio ACXP Stock Details ACXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-167
Closed -$245 – 197
2026
Q2 		$245 Hold
167
– – ﹤0.01% 1789
2026
Q1 		$334 Hold
167
– – ﹤0.01% 1728
2025
Q4 		$433 Buy
167
+100
+149% +$479 ﹤0.01% 1536
2025
Q3 		$5.29K Buy
67
+59
+738% +$356 ﹤0.01% 934
2025
Q2 		$850 Sell
8
-159
-95% -$1.28K ﹤0.01% 1156
2025
Q1 		$1.29K Hold
167
– – ﹤0.01% 1079
2024
Q4 		$2.81K Hold
167
– – ﹤0.01% 702
2024
Q3 		$6.49K Hold
167
– – ﹤0.01% 515
2024
Q2 		$6.49K Hold
167
– – ﹤0.01% 519
2024
Q1 		$7.26K Hold
167
– – ﹤0.01% 461
2023
Q4 		$12.8K Buy
+167
New +$12.6K ﹤0.01% 388

Cornerstone Planning Group's ACXP Position: Q3 2026 in Review

Cornerstone Planning Group sold out of Acurx Pharmaceuticals (ACXP) in Q3 2026, closing a stake of 167 shares — an estimated $245 sold.

Cornerstone Planning Group first reported a position in ACXP in Q4 2023 and held it in 11 quarters. The position peaked at $12.8K in Q4 2023. 0 funds tracked by Wall St. Rank hold ACXP as of Q3 2026.

  • Cornerstone Planning Group reported no remaining Acurx Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Cornerstone Planning Group sold 167 Acurx Pharmaceuticals shares in Q3 2026, an estimated $245.
  • Cornerstone Planning Group first reported a position in Acurx Pharmaceuticals in Q4 2023 and held it in 11 quarters.
  • Cornerstone Planning Group's Acurx Pharmaceuticals position peaked at $12.8K in Q4 2023.
  • 0 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q3 2026.

Based on Cornerstone Planning Group's 13F filing for Q3 2026, filed 16 Oct 2026.